|
Pardes Biosciences Inc (NASDAQ: PRDS) |
|
Pardes Biosciences Inc
PRDS's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Pardes Biosciences Inc 's sales fell
in the second quarter of 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -8.1 %
Pardes Biosciences Inc net loss decreased from $-28 millions, to $-11 millions in second quarter of 2023,
• More on PRDS's Growth
|
|
Pardes Biosciences Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.6 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 40.67.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.21.
• More on PRDS's Valuation
|
|
|
|
|
Pardes Biosciences Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.6 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 40.67.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.21.
Pardes Biosciences Inc Price to Book Ratio is at 0.84 lower than Industry Avg. of 78.2. and higher than S&P 500 Avg. of 0.01
• More on PRDS's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com